Anavex Life Sciences Corp (FRA:12X1)
€ 3.495 0.164 (4.92%) Market Cap: 299.15 Mil Enterprise Value: 165.79 Mil PE Ratio: 0 PB Ratio: 2.31 GF Score: 34/100

Anavex Life Sciences Corp at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript

Apr 27, 2022 / 03:00PM GMT
Release Date Price: €8.7 (+0.39%)
William Wood
B. Riley Securities - Analyst

Hi, good morning. This is William Wood from the B. Riley healthcare team, and I'd like to thank the audience for joining us at day one of the B. Riley Virtual Neuro & Ophthalmology Conference. For our next presenting company, I'm delighted to introduce Christopher Missling from Anavex. Christopher, I know there is a lot of interesting things going on at Anavex. And so I'd like to go ahead and to pass you the floor. And so you can take it away.

Christopher Missling
Anavex Life Sciences Corp. - President & CEO

Thank you very much for the very kind introduction, and I'm excited and thankful for the invitation to this conference. The next slide, please, will be forward-looking statement. So I'd like you to read that since we are public company.

So let me introduce you to Anavex. We are a platform company focused in neurological disorders. We understand that neurological chronic conditions are clearly impaired restoration functions and impaired homeostasis. And the good news is that the body has a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot